CO6511201A2 - Anticuerpos anti-cdcp1 humanizados - Google Patents

Anticuerpos anti-cdcp1 humanizados

Info

Publication number
CO6511201A2
CO6511201A2 CO12035757A CO12035757A CO6511201A2 CO 6511201 A2 CO6511201 A2 CO 6511201A2 CO 12035757 A CO12035757 A CO 12035757A CO 12035757 A CO12035757 A CO 12035757A CO 6511201 A2 CO6511201 A2 CO 6511201A2
Authority
CO
Colombia
Prior art keywords
humanized anti
antibodies
cdcp1
cdcp1 antibodies
humanized
Prior art date
Application number
CO12035757A
Other languages
English (en)
Inventor
Johannes Auer
Birgit Bossenmaier
Guy Georges
Alexander Lifke
Ekkehard Moessner
Gerhard Niederfellner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CO6511201A2 publication Critical patent/CO6511201A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados contra la CDCP1 humana (anticuerpos anti-CDCP1), a los métodos para su producción, a las composiciones farmacéuticas que contienen dichos anticuerpos y a los usos de los mismos.
CO12035757A 2009-08-28 2012-02-29 Anticuerpos anti-cdcp1 humanizados CO6511201A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09011046 2009-08-28
EP10000972 2010-02-01

Publications (1)

Publication Number Publication Date
CO6511201A2 true CO6511201A2 (es) 2012-08-31

Family

ID=43086176

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12035757A CO6511201A2 (es) 2009-08-28 2012-02-29 Anticuerpos anti-cdcp1 humanizados

Country Status (24)

Country Link
US (2) US8394928B2 (es)
EP (1) EP2470567A1 (es)
JP (1) JP5647687B2 (es)
KR (1) KR101495407B1 (es)
CN (1) CN102482357B (es)
AR (1) AR077973A1 (es)
AU (1) AU2010288879A1 (es)
BR (1) BR112012004221A2 (es)
CA (1) CA2770161A1 (es)
CL (1) CL2012000524A1 (es)
CO (1) CO6511201A2 (es)
CR (1) CR20120038A (es)
EC (1) ECSP12011701A (es)
HK (1) HK1167412A1 (es)
IL (1) IL217919A0 (es)
MA (1) MA33537B1 (es)
MX (1) MX2012002458A (es)
NZ (1) NZ597664A (es)
PE (1) PE20121063A1 (es)
RU (1) RU2571207C2 (es)
SG (1) SG178886A1 (es)
TW (1) TWI412375B (es)
UA (1) UA106890C2 (es)
WO (1) WO2011023389A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201113037A (en) * 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
JP2014511147A (ja) 2011-02-10 2014-05-12 ロシュ グリクアート アーゲー 改善された免疫療法
WO2014023679A1 (en) 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
BR112016017046A2 (pt) 2014-01-24 2017-10-03 Henry M Jackson Found Advancement Military Medicine Inc Anticorpos contra glicoproteína f de vírus hendra e nipah
US20170158753A1 (en) * 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
CA3047115A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
US10928391B2 (en) * 2017-06-06 2021-02-23 The Cleveland Clinic Foundation CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
WO2019084319A1 (en) 2017-10-25 2019-05-02 The Regents Of The University Of California ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER
CA3118542A1 (en) * 2018-11-09 2020-05-14 Beth Israel Deaconess Medical Center Cdcp1-targeted therapies
BR112021015160A2 (pt) * 2019-02-01 2022-01-18 Fond Per Listituto Oncologico Di Ricerca Ior Métodos de tratamento do câncer de próstata resistente à castração
IL294218A (en) * 2019-12-27 2022-08-01 Chiome Bioscience Inc Antibody against cdcp1
CN117264055A (zh) * 2022-06-14 2023-12-22 上海恒润达生生物科技股份有限公司 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
WO2023246701A1 (zh) * 2022-06-20 2023-12-28 四川汇宇制药股份有限公司 一种抗体及其用途
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1998002462A1 (en) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1329061A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸
WO2002004508A1 (de) 2000-07-07 2002-01-17 Boehringer Ingelheim International Gmbh Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
CA2838062C (en) * 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
AU2004205802B2 (en) 2003-01-22 2009-11-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
CA2787820A1 (en) 2003-02-19 2004-09-02 Novartis Ag Glycoprotein antigen sima135 expressed in metastatic human tumor cells
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20050152894A1 (en) 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
WO2006114700A2 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
US20070031419A1 (en) * 2005-06-30 2007-02-08 Applera Corporation Methods and compositions for treating diseases targeting CDCP1
BRPI0615397B1 (pt) 2005-08-26 2023-10-03 Roche Glycart Ag Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
JP2007112734A (ja) 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體

Also Published As

Publication number Publication date
SG178886A1 (en) 2012-04-27
US20130209455A1 (en) 2013-08-15
KR20120089658A (ko) 2012-08-13
EP2470567A1 (en) 2012-07-04
US20110052582A1 (en) 2011-03-03
ECSP12011701A (es) 2012-03-30
US8394928B2 (en) 2013-03-12
CN102482357B (zh) 2014-06-11
HK1167412A1 (en) 2012-11-30
JP2013502904A (ja) 2013-01-31
JP5647687B2 (ja) 2015-01-07
AR077973A1 (es) 2011-10-05
CL2012000524A1 (es) 2012-08-17
NZ597664A (en) 2013-03-28
MX2012002458A (es) 2012-03-14
UA106890C2 (uk) 2014-10-27
MA33537B1 (fr) 2012-08-01
BR112012004221A2 (pt) 2016-11-29
WO2011023389A1 (en) 2011-03-03
US9346886B2 (en) 2016-05-24
IL217919A0 (en) 2012-03-29
AU2010288879A1 (en) 2012-02-02
RU2571207C2 (ru) 2015-12-20
PE20121063A1 (es) 2012-08-09
RU2012111708A (ru) 2013-10-10
TW201110983A (en) 2011-04-01
CA2770161A1 (en) 2011-03-03
KR101495407B1 (ko) 2015-02-24
TWI412375B (zh) 2013-10-21
CN102482357A (zh) 2012-05-30
CR20120038A (es) 2012-04-18

Similar Documents

Publication Publication Date Title
CO6511201A2 (es) Anticuerpos anti-cdcp1 humanizados
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
CO7081144A2 (es) Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos
ECSP11011387A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
ECSP11010969A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
ECSP11010913A (es) Anticuerpos biespecíficos anti-egfr / anti-igf-1r
CO6630087A2 (es) Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2
AR076194A1 (es) Anticuerpos biespecificos anti-erbb-2/anti-c-met
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
ECSP10010295A (es) Formulacion de anticuerpo
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
CR20160147A (es) Formulaciones de anticuerpos
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
AR089079A1 (es) Formulacion de anticuerpo anti-cd44
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6390001A2 (es) Anticuerpos contra la angiopoyetina 2 humana
CU20090029A7 (es) Derivados de feniloxianilina

Legal Events

Date Code Title Description
FG Application granted